Diurnal Group plc _ Annual Report 2017 Highlights Operational + Primary endpoint successfully met in European Phase III trial where Chronocort ® has completed a Phase III clinical trial in paediatric AI + Infacort ® paediatric use marketing authorisation (PUMA) submitted to the European Medicines Agency (EMA) + First patient dosed in food matrix compatibility study intended to form part of US Phase III registration package for Infacort ® ; expanded global patent estate with first US patent granted for Infacort ® + Completed first phase of establishing the Company’s European commercial infrastructure and implemented the commercial supply chain for Infacort ® + Significant progress in the European Phase III trial of Chronocort ® in CAH, with over 75% of patients enrolled Financial + Operating loss of £12.1m (2016: £7.0m) reflecting increased investment to support the Group’s anticipated development + Cash and cash equivalents and held to maturity financial assets at 30 June 2017 of £19.9m (2016: £30.1m) + Net cash used in operating activities was £10.5m (2016: £5.1m), in line with the Board’s expectations Post-period highlights + In line with regulatory evaluation, submitted responses to “Day 120 questions” received from the EMA following review of the Infacort ® PUMA package + Submitted a proposed Phase III pivotal US registration study design and supporting data package for Chronocort ® to the US Food and Drug Administration.